Salvatore Greco1, Andrea D'Amuri1, Enrico Giorgini1, Francesco Luciani1, Mariarosaria Lopreiato1, Valeria Fortunato1, Alessandro Scopa1, Grazia Vestita1, Eleonora Capatti2, Angelina Passaro3,4. 1. Department of Translational Medicine, University of Ferrara, Via Luigi Borsari, 46, 44121, Ferrara, Italy. 2. Medical Department, University Hospital of Ferrara Arcispedale Sant'Anna, Via Aldo Moro, 8 Cona, 44124, Ferrara, Italy. 3. Department of Translational Medicine, University of Ferrara, Via Luigi Borsari, 46, 44121, Ferrara, Italy. psn@unife.it. 4. Medical Department, University Hospital of Ferrara Arcispedale Sant'Anna, Via Aldo Moro, 8 Cona, 44124, Ferrara, Italy. psn@unife.it.
Abstract
INTRODUCTION: The outbreak by SARS-CoV-2 has rapidly spread worldwide. The need for specific treatments to adequately stop the inflammatory response and its sequelae is day by day more urgent and many therapeutic strategies were performed since COVID-19 burst in the last months. Statins were thought to be effective against this novel coronavirus for their anti-inflammatory properties, even if the real effects on COVID patients are still partially unexplored. METHODS: We retrospectively evaluated 501 adult patients, consecutively admitted to the two COVID-hospitals of Ferrara's territory, and divided them into two groups: ST = patients on statin therapy on admission and NST=patients not on statin therapy on admission. We searched for differences between groups in terms of anamnestic, clinical and laboratory data and then in terms of COVID-19 outcomes. RESULTS: We found significant differences between groups in terms of age, comorbidities, procalcitonin and CPK serum levels: ST patients were older, more comorbid, with lower procalcitonin and higher CPK serum levels. Male sex was, together with the Charlson Comorbidity Index, an independent predictor of needing intensification of care, while age only was a good predictor of in-hospital and 100-day mortality. Differences were also found in the survival functions between the two groups. CONCLUSIONS: After a period of observation of 100 days, ST patients, despite their older age and their greater load of comorbidities, have similar survival functions to NST patients. If adjusted for age and CCI the survival functions of ST group are considerably more favourable than those of the second group.
INTRODUCTION: The outbreak by SARS-CoV-2 has rapidly spread worldwide. The need for specific treatments to adequately stop the inflammatory response and its sequelae is day by day more urgent and many therapeutic strategies were performed since COVID-19 burst in the last months. Statins were thought to be effective against this novel coronavirus for their anti-inflammatory properties, even if the real effects on COVIDpatients are still partially unexplored. METHODS: We retrospectively evaluated 501 adult patients, consecutively admitted to the two COVID-hospitals of Ferrara's territory, and divided them into two groups: ST = patients on statin therapy on admission and NST=patients not on statin therapy on admission. We searched for differences between groups in terms of anamnestic, clinical and laboratory data and then in terms of COVID-19 outcomes. RESULTS: We found significant differences between groups in terms of age, comorbidities, procalcitonin and CPK serum levels: ST patients were older, more comorbid, with lower procalcitonin and higher CPK serum levels. Male sex was, together with the Charlson Comorbidity Index, an independent predictor of needing intensification of care, while age only was a good predictor of in-hospital and 100-day mortality. Differences were also found in the survival functions between the two groups. CONCLUSIONS: After a period of observation of 100 days, ST patients, despite their older age and their greater load of comorbidities, have similar survival functions to NST patients. If adjusted for age and CCI the survival functions of ST group are considerably more favourable than those of the second group.
Authors: Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant Journal: Circulation Date: 2002-08-20 Impact factor: 29.690
Authors: G B John Mancini; Steven Baker; Jean Bergeron; David Fitchett; Jiri Frohlich; Jacques Genest; Milan Gupta; Robert A Hegele; Dominic Ng; Glen J Pearson; Janet Pope; A Yashar Tashakkor Journal: Can J Cardiol Date: 2016-01-14 Impact factor: 5.223
Authors: Stanislaw P Stawicki; Rebecca Jeanmonod; Andrew C Miller; Lorenzo Paladino; David F Gaieski; Anna Q Yaffee; Annelies De Wulf; Joydeep Grover; Thomas J Papadimos; Christina Bloem; Sagar C Galwankar; Vivek Chauhan; Michael S Firstenberg; Salvatore Di Somma; Donald Jeanmonod; Sona M Garg; Veronica Tucci; Harry L Anderson; Lateef Fatimah; Tamara J Worlton; Siddharth P Dubhashi; Krystal S Glaze; Sagar Sinha; Ijeoma Nnodim Opara; Vikas Yellapu; Dhanashree Kelkar; Ayman El-Menyar; Vimal Krishnan; S Venkataramanaiah; Yan Leyfman; Hassan Ali Saoud Al Thani; Prabath Wb Nanayakkara; Sudip Nanda; Eric Cioè-Peña; Indrani Sardesai; Shruti Chandra; Aruna Munasinghe; Vibha Dutta; Silvana Teixeira Dal Ponte; Ricardo Izurieta; Juan A Asensio; Manish Garg Journal: J Glob Infect Dis Date: 2020-05-22
Authors: S Kritas; P Conti; G Ronconi; A Caraffa; C Gallenga; R Ross; I Frydas Journal: J Biol Regul Homeost Agents Date: 2020 March-April, Impact factor: 1.711